US EditionPfizer scraps daily weight loss pill after liver injury in one patient
- Pfizer has discontinued its potential once-daily obesity pill, Danuglipron, after a trial participant experienced a possible drug-induced liver injury that resolved after stopping the treatment.
- The company had planned to move Danuglipron into late-stage testing before this decision was made.
- A company official stated that Pfizer still aims to develop other potential obesity treatments currently in earlier stages of testing.
- Despite drugmakers producing top-selling obesity treatments, many patients struggle to access them due to shortages and insurance issues.
133 Articles
133 Articles
A generation of women are still haunted by WeightWatchers
So long, WeightWatchers – it’s time to step on the scale for the last time. The much-maligned weight loss company is getting ready to file for bankruptcy, according to reports. Insiders have cited the twin pressures of long-running financial woes and the rise of weight loss drugs as the reasons for its looming demise. I won’t miss it. Those of us who grew up in the “nothing tastes as good as skinny feels” noughties grew up in the long shadow of …
Watauga Democrat
Pfizer Ends Testing of Obesity Pill After Possible Liver Injury
Key Takeaways
Pfizer Pulls Plug On Weight Loss Pill Amid Liver Damage Fears
Pfizer announced it is ending its development of its experimental oral GLP-1 drug to treat obesity, the company said on Monday, after a patient in a trial suffered a liver injury potentially caused by the experimental drug known as danuglipron.
Coverage Details
Bias Distribution
- 54% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
